Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) price on Thursday, July 03, rose 0.83% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $1.83.
A look at the stock’s price movement, the close in the last trading session was $1.81, moving within a range at $1.7913 and $1.85. The beta value (5-Year monthly) was 0.506. Turning to its 52-week performance, $23.80 and $1.15 were the 52-week high and 52-week low respectively. Overall, GLMD moved 23.31% over the past month.
Galmed Pharmaceuticals Ltd’s market cap currently stands at around $4.12 million, with investors looking forward to this quarter’s earnings report slated for on 2025-May-22.
Turning to the stock’s technical picture we see that short term indicators suggest on average that GLMD is a 50% Buy. On the other hand, the stock is on average a 50% Sell as suggested by medium term indicators while long term indicators are putting the stock in 50% Sell category.
7 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 3 analyst(s) rate the stock as a Hold, 4 recommend GLMD as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
GLMD’s current price about 6.03% and 20.12% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 60.38, while 7-day volatility ratio is 5.39% and 6.55% in the 30-day chart. Further, Galmed Pharmaceuticals Ltd (GLMD) has a beta value of 0.58.
If we refocus on Galmed Pharmaceuticals Ltd (NASDAQ:GLMD), historical trading data shows that trading volumes averaged 0.35 over the past 10 days and 1.73 million over the past 3 months. The company’s latest data on shares outstanding shows there are 2.26 million shares.
The 2.90% of Galmed Pharmaceuticals Ltd’s shares are in the hands of company insiders while institutional holders own 9.88% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 66910.0 on 2025-06-13, giving us a short ratio of 0.27. The data shows that as of 2025-06-13 short interest in Galmed Pharmaceuticals Ltd (GLMD) stood at 305.0 of shares outstanding, with shares short falling to 0.19 million registered in 2025-05-15. Current price change has pushed the stock -46.28% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the GLMD stock continues to rise going into the next quarter.
